Clinical Trial Search

Primary: Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score — 73.7; 68.8; 71.3; -16.2 score on a scale — p=0.789

Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…

Primary: ADCS-Clinical Global Impression of Change in Agitation (ADCS-CGIC-A) — 3.434; 3.442 score on a scale — p=0.9904

Primary: Mean Change From Baseline in the 4-Item Agitation/Aggression Subscale of the Neuropsychiatric Inventory (NPI-4 A/A) at Week 12 — -5.4; -6.2 units on a scale

Primary: Change in CMAI Total Score — -15.4; -10.0; -11.5 score on a scale — p=0.010

Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015

Primary: Mean Clinical Global Impression of Change (CGIC) at Last Observation — 2.6; 4.5 units on a scale

Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53

Primary: NeuroBehavior Rating Scale-- Agitation — 4.33; 5.26 units on a scale — p=0.036

Primary: Change in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70…

Primary: Change From Baseline to Week 12 in the CMAI Total Score — -22.6; -17.3 score on a scale — p=0.0026

Primary: Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment — -21.6; -17.6; -17.8 units on a scale…

Primary: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. — -11.7; -15.2; -8.0 units on a scale — p=< 0.0001

Primary: Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A). — -4.3; -4.2 units on a scale

Primary: Change From Baseline to Week 12/Early Termination in the Cohen-Mansfield Agitation Inventory (CMAI) Total Score — -18.9; -16.5 units on a scale — p==0.1454

Primary: Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change — 2.5; 2.43 units on a scale

Primary: Number of Participants With Aggression as Determined by the Cohen-Mansfield Agitation Inventory (Aggression Subscale) — 8; 14; 9; 17 participants — p=0.13

Primary: Treatment Emergent Adverse Events (TEAEs) — 53 Participants

Primary: Change From Baseline in Neuropsychiatric Inventory Clinician Version (NPI-C) Sum of Agitation and Aggression Domain Scores (NPI-C A+A) at Day 43: Analyzed Under Estimand…

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) by Severity — 20.9; 13.5; 9.2; 19.8 percentage of participants

Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02

Primary: Dispensing of Psychotropic Medications — 161; 315 Participants — p=0.492

Primary: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation — -5.7; -7.5; -5.4 score on…

Primary: The Frequency of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 90.2; 90.3 Percentage of percipitante

Primary: Success Rate of Adherence — 2; 6; 7 Participants — p=0.12

Primary: Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score — -5.4; -7.1; -2.9; -6.8 score on a scale — p=0.0813

Primary: Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change…

Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802

Primary: Imagined Interactions: Specificity — 16.87; 16.33; 16.49; 16.20 Scores on a scale — p=0.70

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 8; 5; 1 Participants